Results 151 to 160 of about 249,219 (350)
Fabry Disease (α-Galactosidase A Deficiency): Renal Involvement and Enzyme Replacement Therapy [PDF]
, 2001 Robert J. Desnick +2 more
openalex +1 more source
Advanced Functional Materials, EarlyView.This study presents a microfluidic brain microvascular network‐on‐chip (BMVasChip) to investigate endothelial barrier dysfunction caused by flavivirus non‐structural protein 1 (NS1), including virus‐ and time‐dependent vascular damage, leakiness, and dysfunction.
Monika Rajput +5 more
wiley +1 more source
Clinical monitoring after cessation of enzyme replacement therapy in m. gaucher [PDF]
, 2001 Stephan vom Dahl +2 more
openalex +1 more source
Advanced Functional Materials, EarlyView.Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang +9 more
wiley +1 more source
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy [PDF]
, 2002 Beth L. Thurberg +7 more
openalex +1 more source
Transducer Materials Mediated Deep Brain Stimulation in Neurological Disorders
Advanced Functional Materials, EarlyView.This review discusses advanced transducer materials for improving deep brain stimulation (DBS) in neurological disorders. These materials respond to light, ultrasound, or magnetic fields, enabling precise, less invasive neuromodulation. Their stimulus‐responsive properties enhance neural control and adaptive therapy, paving the way for next‐generation ...
Di Zhao +5 more
wiley +1 more source
Enzyme replacement therapy for Fabry disease: proving the clinical benefit [PDF]
, 2002 Frank Breunig
openalex +1 more source